Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:AKRONASDAQ:AXSMOTCMKTS:CLXPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$18.16-1.3%$20.57$10.21▼$31.50$4.34B0.473.68 million shs4.94 million shsAKROAkero Therapeutics$56.19-0.2%$47.62$21.02▼$59.56$4.48B-0.161.04 million shs3.83 million shsAXSMAxsome Therapeutics$103.36+0.8%$106.65$72.21▼$150.00$5.09B0.48668,958 shs1.18 million shsCLXPFCybin$8.15-5.0%$7.50$0.49▼$3.38$1.21BN/A551,962 shs184,167 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+2.37%-9.06%-8.47%+62.43%AKROAkero Therapeutics0.00%+3.67%+10.13%+38.81%+139.51%AXSMAxsome Therapeutics0.00%+2.65%-1.49%-11.38%+28.40%CLXPFCybin0.00%+4.76%+1.12%+21.28%+2,907.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.0268 of 5 stars3.72.00.00.02.52.53.1AKROAkero Therapeutics3.528 of 5 stars3.51.00.04.71.90.80.0AXSMAxsome Therapeutics4.6331 of 5 stars4.51.00.04.51.44.20.6CLXPFCybinN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6752.35% UpsideAKROAkero Therapeutics 3.00Buy$82.5046.82% UpsideAXSMAxsome Therapeutics 3.06Buy$172.3366.73% UpsideCLXPFCybin 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLXPF, AXSM, AKRO, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.005/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/14/2025AXSMAxsome TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/7/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$200.00 ➝ $180.005/6/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$160.00 ➝ $165.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M10.17$0.54 per share33.55$1.48 per share12.27AKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AAXSMAxsome Therapeutics$385.69M13.20N/AN/A$1.18 per share87.59CLXPFCybin$680K1,780.99N/AN/A$0.44 per share18.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8521.3626.32N/A45.01%47.16%30.51%8/6/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.77N/A36.65N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)CLXPFCybin-$24.42M-$0.24N/AN/AN/AN/AN/AN/AN/ALatest CLXPF, AXSM, AKRO, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ACLXPFCybinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36AKROAkero Therapeutics0.0316.8016.80AXSMAxsome Therapeutics3.482.031.96CLXPFCybinN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AKROAkero TherapeuticsN/AAXSMAxsome Therapeutics81.49%CLXPFCybin0.01%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%AKROAkero Therapeutics7.07%AXSMAxsome Therapeutics22.40%CLXPFCybinN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million229.90 millionOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableAXSMAxsome Therapeutics38049.24 million38.21 millionOptionableCLXPFCybin50148.60 millionN/ANot OptionableCLXPF, AXSM, AKRO, and ADMA HeadlinesRecent News About These CompaniesCybin (OTCMKTS:CLXPF) Trading Down 5.1% - What's Next?June 11, 2025 | marketbeat.comCybin gears up for Phase 3 trial in depression treatmentOctober 3, 2024 | uk.investing.comCYBN Stock Earnings: Cybin Beats EPS for Q1 2024August 9, 2024 | investorplace.comCybin bags breakthrough tag for psychedelic depression drugAugust 4, 2024 | pharmaphorum.comPCYBN Stock Earnings: Cybin Beats EPS for Q4 2023June 27, 2024 | investorplace.comCybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programsSeptember 14, 2023 | finance.yahoo.comCybin Announces Last Subject Dosed in Part B of its Phase 1 ... - Business WireMay 9, 2023 | news.google.comNAMA approves CPT code for psychedelic therapies - Seeking AlphaMay 2, 2023 | news.google.comNPsychedelic Drugs Global Market Report 2023: Featuring Pfizer Inc ... - PR NewswireApril 27, 2023 | news.google.comNDagga firm Cilo Cybin prepares for clinical trials in SA as it again ... - News24April 23, 2023 | news.google.comNPsychedelic Stock Gainers And Losers From April 18, 2023 - msnNOWApril 19, 2023 | news.google.comNSouth African Cannabis Firm Wins Malaysian Backer in New Listing ... - BloombergApril 19, 2023 | news.google.comNPsychedelic Medicine Market is poised to grow at a CAGR of +7 ... - Digital JournalApril 18, 2023 | news.google.comNCybin (CYBN) Stock: Headcount Reduction Insufficient To Ease ... - Seeking AlphaApril 11, 2023 | news.google.comNPsychedelics For Major Depressive Disorder And Anxiety Disorders ... - BenzingaApril 3, 2023 | news.google.comNPsychedelic Drugs Market to See Massive Growth by 2031 | Cybin ... - Digital JournalMarch 25, 2023 | news.google.comNGHRS and Cybin Lead the Way in Psychedelic Medicine Market - Best StocksMarch 25, 2023 | news.google.comNIt's Survival of the Fittest among Psychedelic Start-Ups - Lucid NewsMarch 24, 2023 | news.google.comNIs Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year? - Zacks Investment ResearchMarch 22, 2023 | news.google.comNAlcohol Use Disorder Market to Register Stunning Growth During ... - Digital JournalMarch 21, 2023 | news.google.comNSeelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today - Compass Pathways (NASDAQ:CMPS), GH Res - BenzingaMarch 16, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLXPF, AXSM, AKRO, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$18.16 -0.24 (-1.30%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$18.51 +0.35 (+1.92%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Akero Therapeutics NASDAQ:AKRO$56.19 -0.09 (-0.16%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$59.56 +3.37 (+6.00%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Axsome Therapeutics NASDAQ:AXSM$103.36 +0.79 (+0.77%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$102.22 -1.14 (-1.10%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Cybin OTCMKTS:CLXPF$8.15 -0.43 (-5.01%) As of 06/27/2025Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
